United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

27 Feb 2017
Change (% chg)

$0.60 (+4.89%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Get access to over 18 million research reports from over 1,700 sources.

For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.

Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.

Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:

  • ownership
  • filings
  • deals
  • private equity
  • third-party document and information retrieval
  • estimates
  • fundamentals
  • economics
  • events
  • news
  • and much, much more…

Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.

More From Around the Web

Name Age Since Current Position

Connie Matsui

62 2016 Chairman of the Board

Helen Torley

53 2014 President, Chief Executive Officer, Director

Laurie Stelzer

48 2015 Chief Financial Officer, Senior Vice President

Mark Gergen

53 2016 Chief Operating Officer, Senior Vice President

Harry Leonhardt

59 2015 Senior Vice President, Chief Compliance Officer, General Counsel